Tilray Inc (TLRY) Expected to Post Quarterly Sales of $24.04 Million
Equities research analysts expect that Tilray Inc (NASDAQ:TLRY) will announce $24.04 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Tilray’s earnings, with the lowest sales estimate coming in at $19.94 million and the highest estimate coming in at $32.80 million. The firm is expected to announce its next earnings results on Monday, June 17th.
According to Zacks, analysts expect that Tilray will report full-year sales of $228.10 million for the current financial year, with estimates ranging from $194.21 million to $314.90 million. For the next fiscal year, analysts anticipate that the firm will report sales of $481.08 million, with estimates ranging from $380.15 million to $737.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover Tilray.
Tilray (NASDAQ:TLRY) last issued its earnings results on Monday, March 18th. The company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.19). Tilray had a negative return on equity of 58.43% and a negative net margin of 157.05%. The business had revenue of $15.50 million during the quarter, compared to analysts’ expectations of $12.85 million. Tilray’s revenue for the quarter was up 203.9% on a year-over-year basis.
Shares of NASDAQ TLRY traded down $1.71 during midday trading on Monday, hitting $48.97. 1,931,623 shares of the company’s stock traded hands, compared to its average volume of 2,491,609. Tilray has a 1 year low of $20.10 and a 1 year high of $300.00. The firm has a market capitalization of $4.56 billion and a P/E ratio of -59.72. The company has a quick ratio of 20.75, a current ratio of 21.37 and a debt-to-equity ratio of 2.17.
In related news, CRO Edward Wood Pastorius, Jr. sold 20,578 shares of the business’s stock in a transaction that occurred on Thursday, January 24th. The stock was sold at an average price of $74.21, for a total transaction of $1,527,093.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Mark Castaneda sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $70.43, for a total value of $2,112,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 396,025 shares of company stock valued at $27,310,113 in the last ninety days.
Several large investors have recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Tilray by 20.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,200 shares of the company’s stock valued at $79,000 after acquiring an additional 200 shares during the period. Toronto Dominion Bank bought a new position in shares of Tilray during the 4th quarter valued at approximately $27,000. IFP Advisors Inc grew its stake in shares of Tilray by 61.0% during the 4th quarter. IFP Advisors Inc now owns 1,729 shares of the company’s stock valued at $130,000 after acquiring an additional 655 shares during the period. Bank of America Corp DE grew its stake in shares of Tilray by 48.9% during the 4th quarter. Bank of America Corp DE now owns 2,019 shares of the company’s stock valued at $143,000 after acquiring an additional 663 shares during the period. Finally, Captrust Financial Advisors bought a new position in shares of Tilray during the 3rd quarter valued at approximately $103,000. Institutional investors own 7.91% of the company’s stock.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Further Reading: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.